+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Scleroderma Diagnostics & Therapeutics Market - Global Forecast 2026-2032- Product Image
Scleroderma Diagnostics & Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Scleroderma Diagnostics & Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012574
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Scleroderma Diagnostics & Therapeutics Market is projected to reach USD 2.48 Billion in 2026. It is expected to continue growing at a CAGR of 6.68%, reaching USD 3.67 Billion by 2032.

Scleroderma, also known as systemic sclerosis, is a heterogeneous autoimmune disease characterized by vascular dysfunction, immune activation, and progressive fibrosis. Clinical presentation ranges from limited cutaneous disease with prominent vascular complications to diffuse cutaneous disease with substantial risks involving the lungs, kidneys, gastrointestinal tract, and heart. Diagnosis remains clinically complex because symptoms overlap with other connective-tissue disorders and disease progression varies considerably among patients.

Management therefore depends on earlier recognition, organ-specific assessment, longitudinal monitoring, and coordinated care across rheumatology, pulmonology, cardiology, nephrology, dermatology, gastroenterology, and rehabilitation services. The therapeutic approach generally combines symptom control, prevention or treatment of organ damage, management of vascular complications, and supportive care rather than relying on a single disease-modifying intervention.

From Symptom Management to Multidisciplinary, Organ-Based Care

The care landscape is shifting toward structured risk assessment and organ-based treatment pathways. High-resolution chest imaging, pulmonary function testing, echocardiography, nailfold assessment, autoantibody testing, and validated clinical measures increasingly support earlier identification of pulmonary, cardiac, renal, vascular, and gastrointestinal involvement. These tools are most useful when incorporated into repeatable surveillance protocols rather than used as isolated diagnostic procedures.

Treatment decisions are also becoming more phenotype-sensitive. Clinicians increasingly distinguish patients according to cutaneous burden, interstitial lung disease risk, vascular complications, inflammatory activity, and established fibrosis. This is encouraging more deliberate sequencing of immunomodulatory, antifibrotic, vasodilator, gastrointestinal, renal, and rehabilitative interventions, while placing greater emphasis on safety monitoring and shared decision-making.

Artificial Intelligence Strengthens Detection, Stratification, and Longitudinal Monitoring

Artificial intelligence can support scleroderma care by identifying patterns across imaging, pulmonary function data, laboratory results, digital photographs, electronic health records, and patient-reported outcomes. Potential applications include automated quantification of lung abnormalities, recognition of skin changes, classification of disease phenotypes, detection of deterioration, and prioritization of patients for specialist review. These tools may be particularly valuable where specialist capacity is limited or where subtle progression is difficult to detect through single-visit assessment.

Clinical value will depend on representative training data, transparent validation, interoperability, and prospective evaluation against meaningful outcomes. Algorithms should complement-not replace-clinical judgment, particularly because disease manifestations differ across ancestry, age, sex, comorbidity, treatment history, and care setting. Governance should address privacy, bias, explainability, cybersecurity, and the risk that automated outputs could reinforce unequal access to diagnostic testing or specialist services.

Regional Insights: Uneven Specialist Access Shapes Diagnostic and Treatment Pathways

North America benefits from established specialist networks, advanced imaging, multidisciplinary centers, and broad access to complex therapies, although affordability, insurance design, and geographic disparities can delay care. Europe has strong academic expertise and coordinated clinical research capabilities, but access and implementation vary across health systems. Asia-Pacific combines sophisticated tertiary services in several markets with substantial rural and resource constraints elsewhere, making referral pathways and scalable monitoring especially important.

Latin America faces challenges involving specialist distribution, diagnostic capacity, reimbursement, and continuity of care, while regional centers can support growing expertise and collaboration. The Middle East is expanding tertiary and specialty services, with access differing by country and population group. Africa continues to require stronger awareness, referral infrastructure, laboratory capacity, and long-term follow-up, creating an important role for training, telemedicine, and context-appropriate diagnostic protocols.

Group Insights: Economic and Political Blocs Reveal Different Access Priorities

ASEAN countries show varied levels of specialist availability, diagnostic infrastructure, and reimbursement, making shared training, referral networks, and adaptable screening pathways valuable. BRICS members encompass major differences in health-system scale and resources; priorities include earlier recognition, domestic research capacity, affordable diagnostics, and reliable access to organ-protective care. The European Union can benefit from cross-border research, harmonized evidence generation, and efforts to reduce variation in specialist access.

The G7 has strong capabilities in clinical research, advanced diagnostics, and complex care, but must continue addressing affordability, aging populations, and inequities affecting underserved communities. GCC countries are developing specialized healthcare capacity and can strengthen regional centers of excellence, workforce development, and coordinated registries. NATO members span diverse health systems, yet collaboration on preparedness, digital health standards, and continuity of care can support patients whose treatment is disrupted by mobility, conflict, or system fragmentation.

Country Insights: Distinct Health-System Conditions Influence Scleroderma Care

Australia combines strong specialist expertise with geographic dispersion that makes telehealth and coordinated referral important. Brazil and Mexico face substantial regional variation in access and benefit from strengthening diagnostic pathways beyond major urban centers. Canada and the United States have advanced specialty care and research capacity, while affordability, coverage, and distance can still influence treatment continuity. China and India are expanding specialist and research capabilities, with persistent differences between metropolitan and rural services.

France, Germany, Italy, Spain, and the United Kingdom have established rheumatology networks and public or social-insurance structures, but implementation, waiting times, and access to specialized services can vary. Japan and South Korea have sophisticated tertiary care and diagnostic capabilities, alongside needs related to aging, long-term monitoring, and consistent multidisciplinary coordination. Russia faces geographic and infrastructure challenges that can affect specialist access and continuity. Across all listed countries, earlier referral, standardized organ screening, patient education, and longitudinal registries remain practical priorities.

Action Priorities for Leaders: Build Earlier, More Coordinated, Data-Enabled Care

Industry leaders should prioritize solutions that fit clinical workflows and improve measurable patient outcomes. This includes validated tools for early recognition, standardized screening for organ involvement, interoperable disease registries, and decision support that helps clinicians track change over time. Diagnostic and therapeutic programs should be designed around patient phenotypes and care pathways rather than isolated products or single-organ endpoints.

Partnerships with specialist centers, patient organizations, payers, and public health systems can improve referral, education, adherence, and equitable access. Organizations developing artificial-intelligence applications should use diverse datasets, prospective validation, human oversight, and clear performance reporting. Leaders should also support clinician training, remote monitoring where appropriate, real-world evidence generation, and service models that reduce delays between symptom onset, diagnosis, and specialist treatment.

Research Methodology: Evidence-Led Synthesis of Disease, Care, and Access Dynamics

This executive summary uses a structured qualitative synthesis of established clinical understanding of scleroderma, including its heterogeneous manifestations, diagnostic practices, organ complications, treatment principles, care-delivery requirements, and health-system variation. Insights are organized across disease management, technology adoption, geography, economic and political groupings, and country-level implementation conditions.

The approach emphasizes clinically recognized patterns and avoids unsupported numerical claims. Regional and country observations are framed as health-system considerations rather than rankings or projections. Artificial-intelligence implications are presented as potential applications requiring clinical validation, governance, and equitable implementation. Interpretation should be supplemented with current clinical guidelines, regulatory decisions, peer-reviewed evidence, and locally specific access data before operational or investment decisions are made.

Conclusion: Earlier Recognition and Coordinated Monitoring Are Central to Better Outcomes

Scleroderma diagnostics and therapeutics are advancing toward more precise, organ-focused, and longitudinal care. Progress depends not only on new medicines or diagnostic technologies, but also on recognizing disease earlier, monitoring high-risk organs consistently, coordinating multiple specialties, and supporting patients through complex long-term treatment pathways.

The most durable opportunities lie in connecting clinical expertise with validated diagnostics, responsible artificial intelligence, stronger referral systems, and equitable access strategies. Health systems and industry participants that focus on integrated care, evidence quality, patient-centered design, and implementation across diverse settings will be better positioned to address the clinical complexity of scleroderma without relying on unsupported assumptions about disease burden or treatment response.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Scleroderma Diagnostics & Therapeutics Market, by Product
7.1. Introduction
7.2. Instruments
7.2.1. Capillaroscopy Devices
7.2.2. Imaging Systems
7.3. Reagents & Kits
7.4. Software & Services
7.4.1. Consulting Services
7.4.2. Data Analysis Software
8. Scleroderma Diagnostics & Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Antifibrotics
8.2.1. Nintedanib
8.2.2. Pirfenidone
8.3. Biologics
8.3.1. Rituximab
8.3.2. Tocilizumab
8.4. Immunosuppressants
8.4.1. Corticosteroids
8.4.2. Cyclophosphamide
8.4.3. Methotrexate
8.5. Vasodilators
8.5.1. Calcium Channel Blockers
8.5.2. Endothelin Receptor Antagonists
9. Scleroderma Diagnostics & Therapeutics Market, by Diagnosis Type
9.1. Introduction
9.2. Autoantibody Tests
9.2.1. Anti-Scl-70
9.2.2. Anticentromere
9.3. Biomarker Assays
9.4. Capillaroscopy
9.5. Imaging
9.5.1. High Resolution Ct
9.5.2. Ultrasound
9.6. Molecular Diagnostics
10. Scleroderma Diagnostics & Therapeutics Market, by Disease Form
10.1. Introduction
10.2. Diffuse Cutaneous
10.3. Limited Cutaneous
11. Scleroderma Diagnostics & Therapeutics Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Hospitals
11.4. Research Institutes
11.5. Specialty Clinics
12. Scleroderma Diagnostics & Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Online
12.3. Offline
13. Scleroderma Diagnostics & Therapeutics Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Scleroderma Diagnostics & Therapeutics Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Scleroderma Diagnostics & Therapeutics Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. Antibodies Incorporated
17.4. AstraZeneca PLC
17.5. Bayer AG
17.6. Bio-Rad Laboratories, Inc.
17.7. Biogen Inc.
17.8. Boehringer Ingelheim Pharmaceuticals, Inc.
17.9. Bristol-Myers Squibb Company
17.10. Eli Lilly and Company
17.11. Exagen Inc.
17.12. F. Hoffmann-La Roche Ltd.
17.13. Galapagos NV
17.14. Gilead Sciences, Inc.
17.15. GSK plc
17.16. Merck & Co., Inc.
17.17. Myriad Genetics, Inc.
17.18. Novartis AG
17.19. PerkinElmer Holdings, LLC
17.20. Pfizer Inc.
17.21. Regeneron Pharmaceuticals, Inc.
17.22. Takeda Pharmaceutical Company Limited
17.23. Thermo Fisher Scientific Inc.
17.24. Trinity Biotech plc
18. Key Experts
List of Figures
FIGURE 1. Global Scleroderma Diagnostics & Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Scleroderma Diagnostics & Therapeutics Market, Research Design
FIGURE 3. Global Scleroderma Diagnostics & Therapeutics Market, Research Framework
FIGURE 4. Global Scleroderma Diagnostics & Therapeutics Market, Data Triangulation
FIGURE 5. Global Scleroderma Diagnostics & Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2025 vs 2032 (%)
FIGURE 9. Global Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2025 vs 2032 (%)
FIGURE 11. Global Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2025 vs 2032 (%)
FIGURE 13. Global Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 17. Global Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Scleroderma Diagnostics & Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Scleroderma Diagnostics & Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Scleroderma Diagnostics & Therapeutics Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Scleroderma Diagnostics & Therapeutics Market Segmentation & Coverage
TABLE 2. Global Scleroderma Diagnostics & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Capillaroscopy Devices Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Capillaroscopy Devices Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Capillaroscopy Devices Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Imaging Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Imaging Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Imaging Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Reagents & Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Reagents & Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Reagents & Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Software & Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Software & Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Software & Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Consulting Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Consulting Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Consulting Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Data Analysis Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Data Analysis Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Data Analysis Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 26. Global Antifibrotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Antifibrotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Antifibrotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Nintedanib Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Nintedanib Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Nintedanib Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Pirfenidone Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Pirfenidone Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Pirfenidone Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Rituximab Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Rituximab Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Rituximab Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Tocilizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Tocilizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Tocilizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Immunosuppressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Immunosuppressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Immunosuppressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Cyclophosphamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Cyclophosphamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Cyclophosphamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Methotrexate Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Methotrexate Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Methotrexate Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Vasodilators Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Vasodilators Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Vasodilators Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Calcium Channel Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Calcium Channel Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Calcium Channel Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Endothelin Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Endothelin Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Endothelin Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 66. Global Autoantibody Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Autoantibody Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Autoantibody Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Anti-Scl-70 Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Anti-Scl-70 Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Anti-Scl-70 Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Anticentromere Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Anticentromere Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Anticentromere Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Biomarker Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Biomarker Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Biomarker Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Capillaroscopy Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Capillaroscopy Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Capillaroscopy Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global High Resolution Ct Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global High Resolution Ct Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global High Resolution Ct Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Ultrasound Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Ultrasound Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Ultrasound Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Molecular Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Molecular Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Molecular Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 94. Global Diffuse Cutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Diffuse Cutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Diffuse Cutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Limited Cutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Limited Cutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Limited Cutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. North America Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. North America Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 138. North America Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 139. North America Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 140. North America Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 141. North America Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 142. North America Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 143. North America Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 144. North America Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 145. North America Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 146. North America Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 147. North America Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 148. North America Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 149. North America Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. North America Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 153. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 154. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 155. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 156. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 157. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 158. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 159. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 160. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 161. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 162. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 163. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 164. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Latin America Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 168. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 169. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 170. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 171. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 172. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 173. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 174. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 175. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 176. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 177. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 178. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 179. Europe Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Europe Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 183. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 184. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 185. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 186. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 187. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 188. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 189. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 190. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 191. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 192. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 193. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 194. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Middle East Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 197. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 198. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 199. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 200. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 201. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 202. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 203. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 204. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 205. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 206. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 207. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 208. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 209. Africa Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 210. Africa Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 211. Global Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 213. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 214. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 215. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 216. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 217. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 218. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 219. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 220. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 221. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 222. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 223. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 224. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 225. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. ASEAN Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 229. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 230. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 231. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 232. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 233. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 234. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 235. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 236. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 237. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 238. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 239. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 240. GCC Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. GCC Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 244. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 245. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 246. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 247. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 248. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 249. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 250. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 251. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 252. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 253. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 254. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 255. European Union Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. European Union Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 257. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 258. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 259. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 260. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 261. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 262. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 263. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 264. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 265. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 266. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 267. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 268. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 269. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 270. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. BRICS Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 273. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 274. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 275. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 276. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 277. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 278. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 279. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 280. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 281. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 282. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 283. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 284. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 285. G7 Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. G7 Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 287. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 288. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 289. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 290. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 291. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 292. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 293. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 294. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 295. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 296. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 297. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 298. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 299. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 300. NATO Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. NATO Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Global Scleroderma Diagnostics & Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 303. United States Scleroderma Diagnostics & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 304. United States Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 305. United States Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 306. United States Scleroderma Diagnostics & Therapeutics Market Size, by Software & Services, 2017-2032 (USD Million)
TABLE 307. United States Scleroderma Diagnostics & Therapeutics Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 308. United States Scleroderma Diagnostics & Therapeutics Market Size, by Antifibrotics, 2017-2032 (USD Million)
TABLE 309. United States Scleroderma Diagnostics & Therapeutics Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 310. United States Scleroderma Diagnostics & Therapeutics Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 311. United States Scleroderma Diagnostics & Therapeutics Market Size, by Vasodilators, 2017-2032 (USD Million)
TABLE 312. United States Scleroderma Diagnostics & Therapeutics Market Size, by Diagnosis Type, 2017-2032 (USD Million)
TABLE 313. United States Scleroderma Diagnostics & Therapeutics Market Size, by Autoantibody Tests, 2017-2032 (USD Million)
TABLE 314. United States Scleroderma Diagnostics & Therapeutics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 315. United States Scleroderma Diagnostics & Therapeutics Market Size, by Disease Form, 2017-2032 (USD Million)
TABLE 316. United States Scleroderma Diagnostics & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 317. United States Scleroderma Diagnostics & Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 318. Canada Scleroderma Diagnostics & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 319. Canada Scleroderma Diagnostics & Therapeutics Market Size, by Product, 2017-2032 (USD Million)
TABLE 320. Canada Scleroderma Diagnostics & Therapeutics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 321. Canada Scleroderma Diagnostics & Therapeutics Market Size, by Soft

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Antibodies Incorporated
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GSK plc
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • PerkinElmer Holdings, LLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc

Table Information

Report AttributeDetails
No. of Pages183
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.67 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report - Product Image

Scleroderma Diagnostics and Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Scleroderma Diagnostics and Therapeutics Market Report 2026 - Product Image

Scleroderma Diagnostics and Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Scleroderma Therapeutics Market Outlook 2026-2034: Market Share, and Growth Analysis by Disease Type (Systemic Scleroderma, Localized Scleroderma), Drug Class, Route of Administration, Distribution Channel - Product Image

Scleroderma Therapeutics Market Outlook 2026-2034: Market Share, and Growth Analysis by Disease Type (Systemic Scleroderma, Localized Scleroderma), Drug Class, Route of Administration, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Localized Scleroderma Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Country, 2025-2035 - Product Image

Localized Scleroderma Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Country, 2025-2035

  • Report
  • Global
From
Systemic Scleroderma Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Systemic Scleroderma Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Market

Scleroderma is a chronic autoimmune disorder that affects the skin and other organs. Dermatological drugs are used to treat the symptoms of scleroderma, including skin thickening, joint pain, and fatigue. These drugs can be divided into two categories: immunosuppressants and biologics. Immunosuppressants are used to reduce inflammation and suppress the immune system, while biologics are used to target specific proteins that are involved in the disease process. The scleroderma drug market is highly competitive, with a number of companies offering treatments for the condition. Some of the major players in the market include Pfizer, Novartis, AbbVie, and Sanofi. These companies offer a range of treatments, including immunosuppressants, biologics, and other drugs. Additionally, there are a number of smaller companies that specialize in scleroderma treatments, such as Galapagos, FibroGen, and Fibrocell. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.